Vita 34 adjusts targets for 2017 and increases capital market communication

– Acquisition-related adjustment of revenues and earnings targets

– Integration of Seracell largely implemented, special effects exclusively in 2017

– Sustained intensification of investor relations activities planned

Leipzig, 8 August, 2017 – Vita 34 AG (ISIN: DE000A0BL849; WKN: A0BL84), the second largest stem cell bank in Europe, adjusts its outlook for the current financial year after the acquisition of former competitor Seracell. Against the backdrop of the initial consolidation of the business figures as of 28 June 2017, the Executive Board of Vita 34 AG now expects revenues between EUR 18.9 and 19.4 million (previously: EUR 17.4 – 17.9 m) and earnings before interest, taxes, depreciation and amortization (EBITDA) between EUR 1.6 to 1.9 million (previously: EUR 2.6 – 2.7 m).

“In the current financial year the acquisition of Seracell only partially contributes to revenues and earnings of Vita 34, due to the initial consolidation as of 28 June”, explains Dr. Wolfgang Knirsch, Chairman of the Management Board of Vita 34 AG. “At the same time, however, all of the one-time effects from the takeover will be included in this year’s profit and loss account. From 2018 onwards, the figures will show that the acquisition of Seracell was an extremely attractive deal for us. “

The new targets already include all the one-time effects associated with the transaction. In detail, this includes transaction costs including costs of the capital increase of EUR 0.3 million as well as integration costs including severance payments and compensation payments of EUR 1.0 million. In addition, the company expects costs of management changes of EUR 0.6 million.

The Management Board expects to fully conclude the integration of Seracell in the current financial year. The location for the cryotank warehouse in Rostock with about 40,000 samples will be maintained until further notice, with the additional storage capacities to react to the future growth of Vita 34. The former administrative center of Seracell in Berlin, on the other hand, will be completely closed by the end of September. From 2018 onwards, therefore, the Management expects no further special effects resulting from the acquisition of Seracell. The company will publish the full-year outlook for 2018 in the first quarter of 2018 with the publication of the preliminary results for 2017.

“With the acquisition of Seracell, we are reaching a new level with regard to our company size,” Dr. Wolfgang Knirsch emphasizes. “We will henceforth reposition ourselves from the capital market as well.” For this reason, the company entrusted the experienced interim manager Ingo Middelmenne with the relaunch of the investor relations activities of Vita 34. “We will proactively approach smallcap investors in the coming weeks and present the new Vita 34,” adds Knirsch. Still in August and September, the management will conduct roadshows and will also present the new equity story more intensively during conferences and individual talks.

Contact:

Ingo Middelmenne
Investor Relations

Vita 34 AG
Deutscher Platz 5a
04103 Leipzig

Phone: +49 (0341) 48792 – 0
Email: ingo.middelmenne@vita34.de

About Vita 34

Vita 34 was founded in 1997 as the first private umbilical cord blood bank in Europe and, as a complete provider, offers collection logistics, preparation and storage of umbilical cord blood and cord tissue. The basis for its successful work is an outstanding position in the technological segment of cryo-preservation. Here, cells and tissue are preserved alive at some -190ºC for long periods of time, and can be used if needed in the context of medical treatment. Some 160,000 families are already taking advantage of this offering and have provided for their children with a stem cell deposit at Vita 34.